The Joint Corp. (JYNT) Earnings

Management highlights

- Re-franchising Initiative Progress * Three announced clinic sale bundles are progressing: 32 of 45 Southern California clinics have completed ownership transfer, with the remaining 13 operating under buyer management service agreements (MSAs) pending lease assignments; 4 Northern California clinics have a signed asset purchase agreement; 6 of 21 Southeast clinics have completed ownership transfer, with the remaining 15 operating under MSAs pending lease assignments. * Once all transfers are finalized, only 3 company-owned/managed clinics will remain, completing the transition to a capital-light pure-play franchisor model. * The company completed 3 regional developer (RD) territory buybacks in Q2, bringing year-to-date total to 4, which has improved market performance and will reduce annual RD royalty expenses by ~$630,000. - Patient Growth and Retention * Q2 2026 delivered the highest patient retention rate in over 5 years, driven by newly introduced flexible membership plan options. * Active member growth improved sequentially each month of 2026 to date; lapsed patient re-acquisition is a core near-term focus, with targeted marketing campaigns active. * New clinic cohorts from 2025 continue to outperform prior year groups, and 2026 new clinics are performing even better, reaching break-even in less than 6 months on average. - Marketing and Digital Optimization * Messaging prioritizes pain relief, mobility improvement, and high-quality patient experience to attract longer-tenured members; efforts to personalize experience for high-value members are underway. * AI search engine optimization work has maintained an AI visibility score in the high 70s, outperforming competitors on key search terms, driving higher quality organic traffic to clinic microsites. * Over 500 clinics have rolled out $5 and $10 membership price increases to date, with no meaningful patient pushback observed. - Capital Allocation * Discipline balanced deployment is prioritized: the company repurchased ~$677,000 in shares during Q2, with $3.8 million remaining under the approved $12 million share repurchase authorization. * The balance sheet remains strong: $22.2 million in unrestricted cash, a $20 million fully undrawn line of credit maturing in 2029. - Long-Term Strategic Direction * Post-re-franchising, focus will shift to franchise system support, new patient acquisition, and network expansion, including entry into underpenetrated U.S. markets and potential first international market entry. * The company's model is well-positioned to capture growing consumer demand for longevity, health span, non-invasive whole body care, and wellness services.

Guidance

- Full-year 2026 financial guidance is unchanged from the original March 2026 issuance: system-wide sales are expected to be between $519 million and $552 million, comp sales are projected to range from negative 3% to positive 3%, and consolidated adjusted EBITDA is expected between $12.5 million and $13.5 million. - Comp sales trends are expected to continue improving through the second half of 2026, with fourth quarter comps projected to be higher than third quarter comps. - New franchise clinic opening guidance was revised downward to 22 to 26 openings from the prior 30 to 35 openings; net clinic count at the end of 2026 will be lower than 2025 due to portfolio optimization closures of low-performing sites. - Once re-franchising is fully complete in the second half of 2026, the starting baseline for the new capital-light model is projected to be: 83% to 85% gross margin, 40% to 42% G&A as a percentage of revenue, ~3% of revenue in CapEx, 60% to 70% free cash flow conversion, 19% to 21% adjusted EBITDA margin, and 13% to 15% net income margin; these are starting targets, not long-term goals, with further margin expansion expected in 2027 and beyond. - The company sees long-term potential for over 1,800 franchise clinics in the U.S. alone.

Segment performance

The Joint Corp. is a transitioning franchisor focused on chiropractic care clinics, with overall consolidated Q2 2026 performance as follows: Total consolidated revenue grew 14% YoY to $15.2 million. Cost of revenue was $2.5 million, down 11% YoY. Selling and marketing expenses were $4.9 million, up 40% YoY driven by a shift from local to national marketing investments. G&A expenses were $7.6 million, down 2% YoY, including $500,000 in one-time regional developer (RD) buyback and re-franchising related expenses that will not recur post-transition. Consolidated net income was $653,000, up from $93,000 YoY, a $560,000 year-over-year improvement. Adjusted EBITDA from continuing operations was $1.5 million, up from $88,000 YoY, a $1.4 million increase. System-wide sales were $128 million, down 3.7% YoY. Comp sales were negative 2.8%, a 140 basis point improvement from Q1 2026. Total clinic count was 941 at quarter end, with 5 openings, 7 closures, and 29 re-franchised clinics during the quarter. As a pure-play franchisor, the company derives revenue from franchise royalties and fees; no separate product segment breakdown is provided in the transcript.

Risks & headwinds

No specific new risks or operational failures were discussed in detail on the call. The opening remarks note that all forward-looking statements are subject to inherent risks and uncertainties that could cause actual results to differ materially from projections, with key risk factors detailed in the company's existing SEC filings. The only incremental uncertainty referenced is the ongoing timeline for completing lease assignments for remaining clinic sales in the re-franchising initiative, which has extended the transfer process.

Analyst Q&A

• Q: How is The Joint adapting its digital strategy to succeed in the evolving AI search environment, where click-through rates have declined for many brands?

  A: The company maintains three core practices to stay competitive: it collects local feedback from 260 franchise operators on search performance in their markets, has a dedicated digital team that continuously monitors algorithm changes across all major search platforms, and uses objective third-party measurement to track performance. These efforts have raised the company's AI search visibility score from the low 70s in late 2025 to the high 70s today, keeping it ahead of category competitors.

• Q: What are the top drivers of patient lapse, and what strategies is the company using to win back lapsed patients?

  A: The three top causes of lapse are: patients no longer experiencing pain, limited available time for regular visits, and cost concerns. Most lapsed patients have positive impressions of The Joint's pain relief results and are open to returning, so the company runs targeted marketing promotions to re-engage this group, which has a lower customer acquisition cost than new patients. New flexible membership plans (such as a $35/month single-visit plan with discounted additional visits) have boosted lapsed patient conversion by several hundred basis points.

• Q: What was the sequential trend in comp sales during Q2, what impact has pricing had on results, and how is July 2026 tracking?

  A: Comps improved sequentially through Q2, and July 2026 comps are modestly better than the end of Q2, in line with management's expectation of improving second half trends. Pricing adjustments have had a low single-digit positive impact on Q2 results, and the impact is expected to rise to the high end of the low single-digit range in the second half as more clinics roll out changes. All price increases are applied only to new patients, so the full revenue impact will phase in gradually as membership renews.

• Q: Why is the 19-21% adjusted EBITDA margin framed as a starting point, and where will further margin improvement come from post-re-franchising?

  A: The margin range is a baseline for when the re-franchising transition completes, not a long-term target. Approximately $500,000 in one-time re-franchising and RD buyback expenses are currently in G&A that will not recur after the transition, helping the company hit its 40-42% G&A target. As revenue grows, the fixed-cost capital-light model will generate operating leverage that expands margins over time. Additional cost optimization opportunities will become clearer once all clinic ownership transfers are complete.